PMID- 8154171
OWN - NLM
STAT- MEDLINE
DCOM- 19940512
LR  - 20121019
IS  - 0301-1526 (Print)
IS  - 0301-1526 (Linking)
VI  - 23
IP  - 1
DP  - 1994
TI  - Low-molecular-weight heparins: a decade with the new class of antithrombotic 
      agents.
PG  - 3-9
AB  - Low molecular weight heparins (LMWH) are progressively replacing standard 
      unfractionated heparin (UFH) for prophylaxis of venous thromboembolism, 
      especially following surgery. LMWHs are also being used for treatment of 
      established deep venous thrombosis. The main advantages of this new class of 
      antithrombotic agents as compared with UFH are: 1) a new dosing concept (one 
      single subcutaneous administration instead of two or three), based on improved 
      bioavailability and prolonged half-life; 2) an improved efficacy: safety ratio 
      both in the prophylactic and therapeutic settings. Despite these benefits, some 
      unsolved issues remain to be addressed in specific clinical trials before LMWHs 
      can definitively replace UFH in all previous indications of UFH. These issues 
      include the use of LMWHs in patients with arterial thrombosis or myocardial 
      infarction (e.g. in conjunction with thrombolytic treatment), and in patients 
      with pulmonary embolism. In addition, the easy use of LMWHs opens the way towards 
      outpatient therapy of proximal vein thrombosis but this modality needs to be 
      fully assessed in well-designed clinical trials before definitive recommendations 
      can be given.
FAU - Bounameaux, H
AU  - Bounameaux H
AD  - Department of Medicine, University Hospital of Geneva, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Vasa
JT  - VASA. Zeitschrift fur Gefasskrankheiten
JID - 0317051
RN  - 0 (Blood Coagulation Factors)
RN  - 0 (Heparin, Low-Molecular-Weight)
SB  - IM
MH  - Blood Coagulation Factors/metabolism
MH  - Blood Coagulation Tests
MH  - Heparin, Low-Molecular-Weight/*administration & dosage/adverse effects
MH  - Humans
MH  - Postoperative Complications/blood/prevention & control
MH  - Pulmonary Embolism/blood/*prevention & control
MH  - Risk Factors
MH  - Thrombophlebitis/blood/*prevention & control
RF  - 25
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
PST - ppublish
SO  - Vasa. 1994;23(1):3-9.